Aelis Farma S.A.
AELIS.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.48 | -3.00 | -0.12 |
| FCF Yield | -29.05% | -12.75% | -5.05% | -2.85% |
| EV / EBITDA | -2.31 | -4.36 | -44.60 | -39.56 |
| Quality | ||||
| ROIC | -31.44% | -24.45% | -9.73% | -25.57% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 125.13% |
| Cash Conversion Ratio | 0.90 | 0.90 | 2.28 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.38% | 133.65% | 219.50% | 541.13% |
| Free Cash Flow Growth | -11.07% | 58.09% | -69.42% | 38.57% |
| Safety | ||||
| Net Debt / EBITDA | 0.95 | 1.79 | 2.12 | 4.08 |
| Interest Coverage | -31.64 | -33.64 | -35.24 | -63.76 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -708.49 | 122.17 | 96.02 | 32.19 |